Market Alert : Global Markets Show Mixed Signals Amid Falling Oil Prices, Rising Bond Yields and Persistent US Inflation

Mayank Bansal
Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.

3 ASX Stocks to Watch: Takeover Deal, Medical Device Launch and Copper Mine Approval Drive Gains

3 ASX Stocks to Watch: Takeover Deal, Medical Device Launch and Copper Mine Approval Drive Gains Source: Kapitales Research

Highlights:

  • A specialty pharmaceutical company agreed a AU$6.40 a share cash takeover valuing its equity at about AU$604 million.

  • A medical device maker signed its first two US hospital customers, with quarterly revenue up 437%.

  • A base metals miner won preliminary approval for a long-term tailings facility needed to restart its Queensland copper mine.

Three ASX-listed companies drew strong buying interest this week after announcing a takeover, a commercial launch in the United States and a major environmental approval. Here is what each filing says.

Stocks in Focus

  • Mayne Pharma Group Limited (ASX: MYX) is currently trading at AU$6.010.

  • Imricor Medical Systems, Inc. (ASX: IMR) is currently trading at AU$1.455.

  • 29Metals Limited (ASX: 29M) is currently trading at AU$0.275.

Mayne Pharma Group Limited: Takeover Deal, 17 November 2026

On 17 November 2026, Mayne Pharma signed a scheme implementation deed under which Gedeon Richter will buy all shares for AU$6.40 each in cash. That values the equity at about AU$604 million and is a 99.4% premium to the 16 November close. The board unanimously recommends the deal, subject to there being no superior proposal and a favourable independent expert opinion. Completion also depends on regulatory approvals, a shareholder vote expected in late January 2027, court approval and the sale of the International business. In a separate notice, the company said Dr Brett Wells’ election resolution was withdrawn from the 20 November annual meeting; all other items will proceed.

Imricor Medical Systems, Inc.: Quarterly Report, 13 November 2026

Imricor released its report for the quarter ended 30 September 2026 on 13 November 2026. Its US launch began with Rady Children’s Hospital in San Diego as the first customer, followed two weeks later by Children’s Medical Center Dallas. Revenue was US$188,000, up 437%, and cash stood at US$62.1 million, about AU$90 million. The company also gained US regulatory clearances for use of its NorthStar mapping system and a diagnostic catheter in patients of all ages. It launched a financing program with DLL and won a Philips compatibility declaration that opens a large base of installed MR scanners.

29Metals Limited: Capricorn Copper and Golden Grove, 17 November 2026

On 17 November 2026, 29Metals reported preliminary Queensland approval to build a third tailings storage facility and a water treatment plant at Capricorn Copper, a key step towards restarting the mine. A 20-business-day objection period now applies. Surface water inventory has fallen from 3.4 to 1.1 gigalitres since operations were suspended in March 2024. The restart feasibility study is due by the end of 2026, and the company is weighing streaming, royalty and joint-venture funding. At Golden Grove, October ore mined reached 156,000 tonnes, the best month in over three years, with the mill running at an annualised 1.6 million tonnes.

Final Thoughts

Together, these updates show how deals, product launches and regulatory milestones can quickly change sentiment toward a stock. Investors should read the full announcements before making decisions. This article is general information only and is not financial advice.

Note: All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au